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Abstract
BACKGROUND
Palliative care (PC) has been shown to be beneficial in end stage liver disease
(ESLD), yet the hospitalization data for PC utilization is unknown.
AIM
To identify the trend of PC utilization for the special population of alcoholassociated ESLD patients, factors affecting its use and ascertain its impact on
healthcare utilization.

2022

METHODS
We analyzed around 78 million discharges from the 2007-2014 national inpatient
sample and 2010-2014 national readmission database including adult patients
admitted for decompensated alcohol-associated cirrhosis. We identified patients
with PC consultation as a secondary diagnosis. Odds ratios (OR) and means were
adjusted for confounders using multivariate regression analysis models.

WJH

https://www.wjgnet.com

1817

September 27, 2022

Volume 14

Issue 9

Gupta K et al. Palliative care in alcoholic liver disease

RESULTS
Out of the total 1421849 hospitalizations for decompensated liver cirrhosis, 62782 (4.4%) hospitalizations had a PC consult, which increased from 0.8% (1258) of all alcohol-associated ESLD hospitalizations in 2007 to 6.6% in 2014 (P < 0.01). Patient and hospital characteristics associated with
increased odds of PC utilization were advanced age, lower income, Medicaid coverage, teaching
institution, urban location, length of stay > 3 d, prolonged ventilation, and administration of total
parenteral nutrition (all P < 0.01). Palliative encounters in alcohol-associated ESLD and acute-onchronic liver failure (ACLF) score were associated with increased odds of discharge to a rehabilitation facility, but significantly lower odds of 30-d readmissions (aOR: 0.35, 95%CI: 0.31-0.41),
lower total hospitalization charges and lower mean hospitalization days (all P < 0.01).
CONCLUSION
Inpatient PC is sparingly used for patients with decompensated alcohol related liver disease,
however it has increased over the past decade. PC consultation is associated with lower 30-d
readmission rates on multivariate analysis, and lower hospitalization cost and length of stay in
patients with ACLF score ≥ 2.
Key Words: Alcohol-associated cirrhosis; Palliative care; End stage liver disease; National inpatient sample;
National readmission database
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Alcohol related end stage liver disease (ESLD) carries a poor prognosis and is associated with
significant loss of quality of life and symptom burden. We found that inpatient palliative care is sparingly
used for patients with decompensated alcohol related liver disease, however it has increased over the past
decade. Palliative care referral is associated with decreased hospitalization cost and length of stay in acuteon-chronic liver failure Positive alcohol-associated ESLD patients, as well as decreased rehospitalization
rates in all alcohol associated ESLD patients.

Citation: Gupta K, Hans B, Khan A, Sohail SH, Kapuria D, Chang C. A retrospective study on use of palliative
care for patients with alcohol related end stage liver disease in United States. World J Hepatol 2022; 14(9): 18171829
URL: https://www.wjgnet.com/1948-5182/full/v14/i9/1817.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i9.1817

INTRODUCTION
Cirrhosis represents advanced chronic progressive liver disease, which eventually may lead to end stage
liver disease (ESLD)[1]. ESLD is defined as the manifestations of decompensated liver cirrhosis or liver
failure such as variceal hemorrhage, ascites, spontaneous bacterial peritonitis, hepatocellular carcinoma
(HCC), hepatorenal syndrome, or hepatopulmonary syndrome[2]. While treatments are available to
prevent further fibrosis and liver damage, once the disease reaches the stage of cirrhosis, the only
existing cure is liver transplantation.
Alcoholic liver disease (ALD) presents a significant burden to our healthcare system, and contributes
to 48% of cirrhosis related deaths in the United States. ALD comprises a broad spectrum of disease,
ranging from early ALD to alcohol-associated steatohepatitis and advanced ALD, requiring liver
transplantation. While in recent years, the number of patients with ALD receiving a liver transplant has
increased, it is still a miniscule percentage of the patients with ALD[3]. A study from the United Nation
for Organ Sharing Database found that the number of transplants for ALD was stable between 2002 and
2012, but rose by approximately 177 transplants per year between 2013 and 2015[4]. Meanwhile, the
prevalence of alcohol-associated cirrhosis is increasing in the United States. In a privately insured
population, the alcohol-associated cirrhosis prevalence rate increased by 43% over the course of a 7-year
period from 2009 to 2015[5].
Patients with ESLD often experience symptoms such as abdominal pain secondary to ascites, fatigue,
anorexia, depression and confusion[6]. As a result of the physical and psychological effects of ESLD,
quality of life is often severely impacted. In fact, patients with ESLD have been shown to have a quality
of life similar to patients with end stage heart or lung disease, as well as a symptom burden similar to
patients with colorectal cancer[7,8]. Palliative care (PC) has shown to be effective in improving quality
of life, decreasing economic burden of disease as well as improving survival in oncology, however its

WJH

https://www.wjgnet.com

1818

September 27, 2022

Volume 14

Issue 9

Gupta K et al. Palliative care in alcoholic liver disease

use in advanced liver disease has been limited. A study by Barnes et al[9] showed an early palliative care
referral of only 19% in 74 admitted patients. Only 17% of patients taken off the transplant list were
actually referred to palliative care, and death occurred within 70 h of referral in half of these patients
[10].
Palliative care is of special importance in patients with alcohol-associated liver disease as the life
expectancy of patients with alcohol-associated cirrhosis is very low, 5-year and 10-year survival rates
are 23 percent and 7 percent, respectively[11]. These rates are significantly worse than survival rates for
patients whose cirrhosis was not caused by alcohol. These factors make early intervention by palliative
care greatly beneficial to patients with alcohol-associated cirrhosis.
Due to the combination of disadvantageous positions for alcohol-dependent patients to secure a liver
transplantation, poorer prognosis in this cohort, and the negative association of alcohol-associated liver
disease patients to have a palliative care referral we aimed to study the implications of palliative care
consult for this population[9]. In this study, we evaluate the use of palliative care for patients with
decompensated alcohol-associated liver disease while they are admitted to the hospital for inpatient
care in the United States.

MATERIALS AND METHODS
Data acquisition
We performed a retrospective, multicenter, observational study using data from two national databases,
nationwide inpatient sample (NIS) from 2007 to 2014, and national readmission database (NRD) from
2010 to 2014. We utilized NIS until 2014 because the International Classification of Diseases (ICD) codes
utilized by NIS have differed from the year 2015 to incorporate ICD-10 codes. We used different time
periods for the two databases as NRD came into existence from the year 2010, unlike NIS which began
from 1997. Both of these databases are a part of the healthcare cost and utilization project maintained by
the agency for healthcare research and quality. The NIS is an administrative database consisting (until
2012) of all hospitalizations drawn from a sample of 20% of United States hospitals, and then weighted
to be nationally representative of all United States hospitalizations[12]. NRD represents about half of all
United States Hospitalizations, and provides a national estimate of readmission rates[13].
We performed separate analysis on both of the databases owing to their unique characteristics. The
data cannot be merged from the two databases as the identifying information in both is encoded as
different numbers. The NIS database provides information regarding the index hospital admission and
includes patient demographic data, primary and secondary diagnosis, procedures, hospital characteristics, and inpatient and discharge mortality rates. Each record includes one primary and up to 24
discharge diagnoses, procedure codes, demographic data, hospitalized inpatient mortality indicator,
payer status, total hospitalization charges and length of stay[10]. The NRD in addition to the
information provided by NIS, also assigns a unique, unidentified patient association number to each
patient, and tracks all patients at each hospital in each state throughout the calendar year.

Cohort selection
We used International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to
identify primary and secondary diagnosis codes of interest. To identify patients with end stage alcoholassociated liver disease, an entry was required to have the following diagnosis: (1) Diagnosis code for
alcohol-associated cirrhosis (571.2) along with a diagnosis code for a decompensating event [defined by
ICD-9-CM code of bleeding esophageal varices (456.0, 456.21), ascites (789.5, 789.59), and hepatic
encephalopathy (572.2)]; and (2) Diagnosis code for other cirrhosis (571.5) with an alcohol
disorder/comorbidity (571.1, 291x, 303x, 305x, 790.3, 980x, E860), and an event of decompensation (as
defined above). This combination of ICD-9-CM codes for cirrhosis and complications has a positive
predictive value of 78%, a negative predictive value of 91% for cirrhosis, with a c-statistic of 0.71[14].
We excluded patients who were less than 18 years old at the time of admission or who were
transferred from another health facility. In keeping with the North American Consortium for the Study
of End-Stage Liver Disease (NACSELD) exclusion criteria, we omitted patients with a history of prior
liver transplant, human immunodeficiency virus or actively pregnant. Palliative care consultation was
identified using the ICD codes (ICD 9: V66.7, ICD 10: Z51.5). Other factors such as cirrhosis complications, in-hospital death, medical complications, intensive care unit care, length of hospitalization and
costs were examined as dependent variables. Independent variables included were age, sex, race, payer
source (commercial or health maintenance organization, Medicare, Medicaid, self-pay, or other),
comorbidity, nature of admission (emergent/urgent, or other), hospital bed-size, hospital location (rural
or urban), geographic region and hospital teaching status. Figure 1 depicts the flow of the study cohort.
The diagnostic codes associated with these diagnoses are shown in supporting Table 1.

Variables and statistical analysis
Data were analyzed using Stata 15.0 (StataCorp, College Station, TX). Pearson χ2 test was used to
compare proportions between the patients with PC and without PC. Associations between variables
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Table 1 Baseline characteristics of cohort
Variable

Overall

Patients with palliative
consult

Patients without palliative
consult

Number of patients

973246

47423

925823

Female

276401 (28.4%)

14037 (29.6%)

262933 (28.4%)

< 0.001

Age in yr

54.7 ± 004

57.2 ± 0.1

54.5 ± 0.04

< 0.001

18-35

36010 (3.7%)

1327 (2.8%)

33329 (3.6%)

< 0.001

36-45

108030 (11.1%)

3604 (7.4%)

103692 (11.2%)

< 0.001

46-65

625797 (64.3%)

28975 (61.1%)

595304 (64.3%)

< 0.001

> 66

204381 (21%)

13136 (27.7%)

191645 (20.7%)

< 0.001

White

660834 (67.2%)

33433 (70.5%)

614746 (66.4%)

< 0.001

Black

96351 (9.9%)

4647 (9.8%)

95359 (10.3%)

< 0.001

Hispanic

160585 (16.5%)

6544 (13.8%)

161093 (17.4%)

< 0.001

Other

60341 (6.2%)

2940 (6.2%)

57401 (6.2%)

0.532

0 or 1

118736 (12.2%)

2371 (5%)

116653 (12.6%)

< 0.001

2

46715 (4.1%)

948 (2%)

38884 (4.2%)

< 0.001

3 or more

854509 (87.8%)

45051 (95%)

809169 (87.4%)

< 0.001

$1–$38999

297813 (30.6%)

13894 (29.3%)

283301 (30.6%)

0.003

$39000–$47999

255963 (26.3%)

12946 (27.3%)

245343 (26.5%)

0.004

$48000–$62999

231632 (23.8%)

11144 (23.5%)

220345 (23.8%)

0.133

> $63000

187836 (19.3%)

9389 (19.8%)

178683 (19.3%)

< 0.001

Medicare

341609 (35.1%)

17878 (37.7%)

328667 (35.5%)

< 0.001

Medicaid

260829 (26.8%)

12045 (25.4%)

249046 (26.9%)

< 0.001

Private

255963 (26.3%)

12282 (25.9%)

243491 (26.3%)

< 0.001

Uninsured

114843 (11.8%)

5216 (11%)

109247 (11.8%)

< 0.001

Teaching hospital

514847 (52.9%)

28690 (60.5%)

486982 (52.6%)

< 0.001

Urban hospital

891493 (91.6%)

44387 (93.6%)

847128 (91.5%)

< 0.001

Northeast

177130 (18.2%)

6828 (14.4%)

170351 (18.4%)

< 0.001

Midwest

199515 (20.5%)

9911 (20.9%)

189793 (20.5%)

0.832

South

345502 (35.5%)

16692 (35.2%)

328667 (35.5%)

0.104

West

251097 (25.8%)

13989 (29.5%)

237010 (25.6%)

< 0.001

Small

122628 (12.6%)

4931 (10.4%)

118505 (12.8%)

< 0.001

Medium

258883 (26.6%)

12756 (26.9%)

246268 (26.6%)

0.002

Large

590760 (60.7%)

29734 (62.7%)

561048 (60.6%)

< 0.001

P value

Patient characteristics

Age divided into categories

Race

Charleston comorbidity index

Median income in patient zip code

Insurance provider

Hospital characteristics

Hospital region

Hospital size
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Hospital complications
Variceal bleed

114843 (11.8%)

4789 (10.1%)

110428 (11.9%)

< 0.001

HRS

22619 (7.2%)

14942 (23.8%)

75917 (8.2%)

< 0.001

Hepatic encephalopathy

321171 (33%)

24375 (51.4%)

322186 (34.8%)

< 0.001

Ascites

605359 (62.2%)

34191 (72.1%)

565677 (61.1%)

< 0.001

SBP

23357 (2.4%)

1659 (3.5%)

21293 (2.3%)

< 0.001

Hepatocellular carcinoma

60341 (6.2%)

5927 (12.5%)

49994 (5.4%)

< 0.001

0

495382 (50.9%)

11191 (23.6%)

482353 (52.1%)

< 0.001

1

389298 (40%)

22810 (48.1%)

366625 (39.6%)

< 0.001

2

64234 (6.6%)

8536 (18%)

56475 (6.1%)

< 0.001

3

22384 (2.3%)

4505 (9.5%)

18516 (2%)

< 0.001

4

973 (0.1%)

426(0.9%)

925 (0.1%)

< 0.001

ACLF ≥ 2

89538 (9.2%)

13420 (28.3%)

76843 (8.3%)

< 0.001

Mean ACLF score

0.64

1.21

0.61

< 0.001

NACSELD-ACLF score

HRS: Hepatorenal syndrome; SBP: Spontaneous bacterial peritonitis; NACSELD-ACLF: North American Consortium for the Study of End-Stage Liver
Disease's definition of acute-on-chronic liver failure; ACLF: Acute-on-chronic liver failure.

Figure 1 Inclusion figure. HIV: Human immunodeficiency virus.

were analyzed using cross-tabulations and multivariate logistic regression modeling. Data were
weighted and modified hospital and discharge weights to correct for changes in sampling over time
were applied. Variance estimation was performed using procedures for survey data analysis with
replacement. Strata with one sampling unit were centered at the population mean. Multivariable
regression analysis models were used to adjust the results for potential confounders. Multivariable
regression models were built by including all confounders that were significantly associated with the
outcome of univariable analysis with a cutoff P-value of 0.05. The model controlled for age, sex, race,
median household income of residents in the patient's zip code, insurance, charlson comorbidity index,
hospital bedsize, academic status of hospital, hospital location, length of stay, acute-on-chronic liver
failure (ACLF) score, history of hepatocellular carcinoma, acute infections, transjugular intrahepatic
portosystemic shunt (TIPS) and total parenteral nutrition (TPN). Logistic regression was used for binary
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outcomes and linear regression was used for continuous outcomes.

Outcomes variables
Our primary outcome of interest was the proportion of decompensated liver cirrhosis patients who
received a PC consult during their hospitalization and their trend over the study period. Secondary
outcomes were: (1) All-cause in-hospital mortality; (2) Healthcare total hospital charge; (3) Duration of
hospitalization [Length of stay (LOS) in days], which were all encoded in the data set as unique
variables; and (4) Major in hospital procedures and portal hypertensive complications, and these were
compared between the two groups. We further categorized patients according to the number of organ
failures based upon the NACSELD-ACLF, a bedside tool to predict short-term mortality in ESLD
patients. This score has been previously validated using the NIS. A positive ACLF score is deemed as ≥
2. We also included other complications of cirrhosis such as portal hypertension, hepatorenal syndrome
and spontaneous bacterial peritonitis. We also identified procedures commonly performed in ESLD
hospitalizations such as total parenteral nutrition, TIPS and prolonged mechanical ventilation.

RESULTS
There was a total of 2059524 hospitalizations for alcohol-associated cirrhosis recorded, out of which
973246 met our inclusion criteria of presenting with a portal complication. The majority of the patients
were male (73.1%), white (67%), had a mean Charlson comorbidity index < 3 (83.6%) and belonged to
the age group 46-65 years (68%). The mean age was 54.7 years. A palliative care encounter was recorded
in only 4.8% of cases (n = 47423). On trending the utilization of palliative care, it was observed to have
increased from 0.8% (956) of all ESLD hospitalizations in 2007 to 6.6% (9430) in 2014. Figure 2 depicts the
trend of hospitalizations in both groups.

Factors affecting palliative care encounter
A palliative care encounter was more likely in female patients (29.6% vs 28.4% P < 0.01), patients older
than 65 years (27.7% vs 20.7%, P < 0.01), whites (70.5% vs 66.4%, P < 0.01), Charlson comorbidity score ≥
3 (95% vs 87.4%, P < 0.01) and medicare patients (37.7% vs 35.5%, P < 0.01), but was less likely for
hispanic patients (13.8% vs 17.4%, P < 0.01), patients belonging to the lowest quarter of mean income
(29.3% vs 30.6%, P = 0.003) and patients with medicaid (25.4% vs 26.9%, P < 0.001) or no insurance at all
(11% vs 11.8%, P < 0.01). With regards to hospital characteristics, a significantly higher proportion of
patients receiving palliative care were treated at teaching hospitals (60.5% vs 52.6%, P < 0.01), in urban
locations (93.6% vs 91.5%, P < 0.01), large hospitals (62.7% vs 60.6%, P < 0.01) and in western states
(29.5% vs 25.6%, P < 0.001), whereas patients in northeastern states (14.4% vs 18.4%, P < 0.01) were less
likely to receive an inpatient palliative care consult.
On analyzing complications related with cirrhosis, patients receiving palliative care as inpatients had
a significantly higher proportion of hepatic encephalopathy (51% vs 34 %, P < 0.001), ascites (72% vs
61%, P < 0.001), hepatorenal syndrome (23% vs 8%, P < 0.001), spontaneous bacterial peritonitis (3.5% vs
2.3%, P < 0.001) and HCC (12% vs 5%, P < 0.001), whereas patients with variceal bleeding (10% vs 12%, P
< 0.001) were less likely to receive a palliative care. Palliative care consults were more common in all
patients with North American Consortium for the Study of End-Stage Liver Disease's definition of
acute-on-chronic liver failure (NACSELD-ACLF) score ≥ 1, with the proportion increasing by each grade
(Grade 1: 48.1% vs 39.6%; Grade 2: 18% vs 6.1%; Grade 3: 9.5% vs 2%; Grade 4: 0.9% vs 0.1%, all P <
0.001).
In the palliative care cohort, more people received total parenteral nutrition, or TPN (2.9% vs 1.4%, P
< 0.001) however, a lower number were liver transplant recipients (0.6% vs 1.8%, P < 0.001). There was
no difference in receiving a transjugular intrahepatic systemic shunt, or TIPS (1.2% vs 1.3%, P = 0.359)
between the two groups.
Multivariate logistic regression analysis of predictor variables for palliative consultation associated
with alcohol related ESLD is shown in Table 2. After controlling for all other variables, hepatorenal
syndrome (aOR: 3.4, 95%CI: 3.04-3.81, P < 0.001), ascites (aOR: 1.13, 95%CI: 1.03-1.24, P = 0.007),
spontaneous bacterial peritonitis (SBP) (aOR: 3.32, 95%CI: 2.65-3.86, P < 0.001) and HCC (aOR: 1.78,
95%CI: 1.58-2.00, P < 0.001) were associated with higher odds of palliative care encounter than alcohol
related ESLD patients. Patients with ACLF scores ≥ 2 were associated with higher odds of palliative care
consult (aOR: 1.02 95%CI: 1.00-1.04, P < 0.001). Patient and hospital characteristics associated with
increased palliative care utilization on multivariate regression were advanced age (aOR: 1.02, 95%CI:
1.00-1.04, P < 0.001), female sex (aOR: 1.07, 95%CI: 1.00-1.14, P < 0.001), uninsured (aOR: 1.52, 95%CI:
1.36-1.7, P < 0.001), teaching institution (aOR: 1.4, 95%CI: 1.28-1.53, P < 0.001), hospital bedsize > 400
beds (aOR: 1.25, 95%CI: 1.1-1.41, P < 0.001), and length of stay > 5 d (aOR: 1.18, 95%CI: 1.10-1.26, P <
0.001). Major infections during the hospitalization, as described above, had higher odds of palliative
care use (aOR: 1.58, 95%CI: 1.48-1.69, P < 0.001). Other patient characteristics with increased odds of
palliative consult included mechanical ventilation (OR: 3.32 95%CI: 3.1-3.54, P < 0.01), and administration of TPN (OR: 2.02, 95%CI: 1.8-2.27, P < 0.01).
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Table 2 Multivariate regression for palliative consult
Variable

Adjusted odds ratio

95%CI

P value

Age

1.02

1.00-1.04

< 0.001

Median income in patient zip code
$1-$38999

Reference

$39000-$47999

1.07

0.98-1.16

0.117

$48000-$62999

0.99

0.9-1.08

0.983

> $63000

0.95

0.85-1.02

0.141

Female sex

1.07

1.00-1.14

0.023

Race
Caucasian

Reference

African Americans

0.81

0.72-0.9

< 0.001

Hispanic

0.71

0.64-0.78

< 0.001

Others

0.89

0.78-1.00

0.069

Charleson comorbidity index

1.1

1.08-1.12

< 0.001

Insurance status
Medicare

Reference

Medicaid

1.34

1.19-1.51

< 0.001

Private insurance

1.18

1.08-1.29

< 0.001

Uninsured

1.52

1.36-1.7

< 0.001

Teaching hospital

1.4

1.28-1.53

< 0.001

Bed size
< 250 beds

Reference

251-400 beds

1.24

1.09-1.42

0.001

> 400 Beds

1.25

1.1-1.41

< 0.001

Urban location

0.96

0.83-1.19

0.625

Length of stay by groups
<3d

Reference

3-5 d

0.92

0.84-1.00

0.065

>5d

1.18

1.10-1.26

< 0.001

Rehab transfer

4.07

3.29-5.04

< 0.001

1

2.53

2.35-2.71

< 0.001

2

6.05

5.5-6.66

< 0.001

3

9.86

8.75-11.1

< 0.001

4

10.61

7.32-15.42

< 0.001

ACLF ≥ 2

3.47

3.21-3.74

< 0.001

Hepatocellular carcinoma

1.78

1.58-2.00

< 0.001

Infection

1.58

1.48-1.69

< 0.001

Mechanical ventilation

3.32

3.1-3.54

< 0.001

Total parenteral nutrition

2.02

1.8-2.27

< 0.001

Hepatorenal syndrome

3.4

3.04-3.81

< 0.001

Ascites

1.13

1.03-1.24

< 0.001

ACLF Score
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Spontaneous bacterial peritonitis

3.34

2.65-3.86

< 0.001

Age

1.02

1.00-1.04

< 0.001

Female sex

1.07

1.00-1.14

0.023

Race
Caucasian

Reference

African Americans

0.81

0.72-0.9

< 0.001

Hispanic

0.71

0.64-0.78

< 0.001

Others

0.89

0.78-1.00

0.069

Charleson comorbidity index

1.1

1.08-1.12

< 0.001

Insurance status
Medicare

Reference

Medicaid

1.34

1.19-1.51

< 0.001

Private insurance

1.18

1.08-1.29

< 0.001

Uninsured

1.52

1.36-1.7

< 0.001

Teaching hospital

1.4

1.28-1.53

< 0.001

Bed size
< 250 beds

Reference

251-400 beds

1.24

1.09-1.42

0.001

> 400 Beds

1.25

1.1-1.41

< 0.001

Urban location

0.96

0.83-1.19

0.625

Length of stay by groups
<3d

Reference

3-5 d

0.92

0.84-1.00

0.065

>5d

1.18

1.10-1.26

< 0.001

Rehab transfer

4.07

3.29-5.04

< 0.001

ACLF ≥ 2

3.47

3.21-3.74

< 0.001

ACLF: Acute-on-chronic liver failure.

Effect of palliative care use on hospital outcomes
On multivariate analysis, total hospitalization charges (regression coefficient: $1813, 95%CI: -1106 to
4734, P = 0.224) and length of stay (regression coefficient: 0.342, 95%CI: -1.031 to 1.71, P = 0.625) were
unchanged in patients with PC. Looking at patients who were NACSELD ACLF positive (ACLF ≥ 2), we
saw that palliative care was associated with significantly reduced total hospitalization charges
(regression coefficient: -$8405, 95%CI: -16721 to -90, P = 0.048) and length of stay (regression coefficient:
-2.34 d, 95%CI: -2.88 to -1.81 d, P < 0.001).

Effect of palliative care consult on readmission rates
Utilizing the NRD 2010-2014, a total of 356215 patients with alcohol related ESLD met the inclusion
criteria, out of which 164940 patients were readmitted, leading to a 30-d readmission rate of 46.3%.
Table 3 shows the factors associated with readmission rates. On univariate analysis, we found palliative
care, age, charlson comorbidity index, hospital location, teaching status, ACLF score and infection had a
statistically significant association with readmission rates. We used these factors to analyze the
association of PC with 30-d readmission rate with cox multivariate regression model. PC consult was
associated with significantly lower odds of 30-d readmissions (aOR: 0.35, 95%CI: 0.31-0.41, P < 0.001).
Other factors found to be associated were age (aOR: 0.99, 95%CI: 0.99-0.99, P < 0.001), charlson
comorbidity index (aOR: 1.06, 95%CI: 1.05-1.06, P < 0.001), positive ACLF (aOR: 0.86, 95%CI: 0.81-0.91, P
< 0.001), infection (aOR: 1.09, 95%CI: 1.07-1.13, P < 0.001) and hospital located in rural area (aOR: 0.86,
95%CI: 0.81-0.91, P < 0.001).
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Table 3 Results of regression analysis looking at the factors associated with 30-d readmission rate
Variable

Unadjusted odds ratio

95%CI

P value

Adjusted odds ratio

95%CI

P value

Palliative care

0.36

0.31-0.41

< 0.001

0.35

0.31-0.41

< 0.001

0.99

0.99-0.99

< 0.001

0.99

0.99-0.99

< 0.001

1.06

1.05-1.06

< 0.001

Patient characteristics
Age
Median income in patient zip code
$1-$38999

Reference

$39000-$47999

0.97

0.94-1.01

0.236

$48000-$62999

1

0.97-1.04

0.655

> $63000

1.02

0.99-1.06

0.133

Female sex

1.01

0.99-1.04

0.188

Race
Caucasian

Reference

African-Americans

0.77

0.52-1.12

0.175

Hispanic

0.93

0.65-1.34

0.721

Others

0.76

0.47-1.24

0.282

Mean charlson comorbidity index

1.04

1.03-1.04

< 0.001

Insurance status
Medicare

Reference

Medicaid

1.14

1.11-1.18

< 0.001

Private insurance

0.89

0.86-0.93

< 0.001

Uninsured

0.75

0.71-0.78

< 0.001

ACLF ≥ 2

0.89

0.84-0.95

0.001

0.86

0.81-0.91

< 0.001

Infection

1.07

1.04-1.10

< 0.001

1.09

1.07-1.13

< 0.001

1.05

1.02-1.05

< 0.001

1.02

0.99-1.05

0.208

0.86

0.81-0.91

< 0.001

Hospital characteristics
Teaching hospital
Bed size
< 250 beds

Reference

251-400 beds

1

0.95-1.06

0.723

> 400 Beds

1.02

0.97-1.07

0.37

Rural location

0.85

0.83-0.88

< 0.001

ACLF: Acute-on-chronic liver failure.

DISCUSSION
In this large, nationally representative analysis of patients with alcohol-assocaited ESLD, only a small
proportion of patients (4.4%) received palliative care. The rate is lower as compared to PC consultations
for advanced cancers which was recorded at 9.9% using NIS[15]. While still low, there has been an
encouraging increase in the utilization of palliative care from less than 1% in 2007 to almost 7 % of all
inpatient encounters in 2014. This is comparable to an increase in PC consults in inpatients with allcause ESLD, reported by Rush et al[16] over a similar time period, and can be attributed to the increased
recognition of the role PC plays in improving quality of life and reducing disease burden.
We identified geographical, socioeconomic as well as racial disparities in PC referrals. This may be
due to an incomplete understanding of the concept of palliative care amongst some patient populations,
such as the hispanic population. In addition, access to healthcare services was also a significant factor as
PC referrals were more common in large and urban hospitals. This follows the trend oncologists have
reported amongst minorities and low-income groups[17].
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Figure 2 Trend of palliative consults in hospitalized alcohol-associated end stage liver disease patients.

As expected, sicker patients were more likely to receive palliative consults. Patients with ≥ 4 ACLF
score had ten times higher odds of a palliative consult as compared to patients with a score of zero. The
ACLF score has been shown to have better predictive value. Patients who presented with variceal
bleeding as a symptom of decompensated alcohol related ESLD were less likely to receive PC consults,
this could be because of effective endoscopic interventions available compared to the more insidious
and perhaps more advanced illness indicated by ascites and hepatorenal syndrome. Similarly, patients
with HCC were more likely to receive PC consults, the oncological nature of their disease perhaps
facilitating recognition of the need for palliative care. Hudson et al[18] have introduced a model to
identify patients at high risk of impending death in patients with decompensated cirrhosis, which
included patients with presence of 3 or more factors on admission to the emergency department, a
history of 2 or more admissions in the prior 6 mo, ongoing alcohol use in the context of known alcoholrelated liver disease, unsuitability for liver transplant, and World Health Organization Performance
status 3 or 4 predicted 1-year mortality with a sensitivity of 72%.
Increased PC use seen in patients with prolonged ventilation and TPN suggest a delayed referral to
PC, occurring after significant progression of disease. The timing of palliative care is important, and
early PC has been shown to improve quality of life and prolong survival in other patient populations
[19] and may help avoid aggressive and futile treatments[20]. Previous data has shown that alcoholassociated ESLD patients are more likely to have a delayed PC referral, with young age and recent
alcohol use found to be predictors of late hospice referrals[21]. We saw that inpatients with positive
ACLF score, length of stay and total hospitalization charges were significantly reduced with the use of
PC services. This is likely as patients with positive ACLF score have a 6-mo mortality rate of 90%, thus
meeting the criteria for hospice care as per medicare rules and are likely to have PC involved[22,23]. On
analyzing the national readmission database, we found that PC was associated with a significantly
reduced odds of 30-d readmission in alcohol associated ESLD patients, with an adjusted odds ratio of
0.35 on multivariate analysis, accounting for several factors found to be associated with readmission
rates such as age and ACLF score. We found that the rate of readmissions in our cohort of alcoholassociated ESLD patients with C use was lower than that of all ESLD patients which has been studied
before[24,25]. Also, utilization of PC was lower than all-ESLD patients, where it was 5.3% vs 4.4% for
our cohort of patients.
Our study has several limitations. First, inherent to the nature of our retrospective discharge
database, our analysis is limited by the errors in coding as well as missing data. Additionally, we were
unable to identify interventions performed to alleviate decompensating events, and whether successful
interventions reduced the referral to PC. The period over which our data has been collected has also
witnessed changes in the management of alcohol related ESLD, with a significant increase in ALD liver
transplantation. While survival in alcohol-associated cirrhosis remains low, increased transplantation
potentially reduces the number of alcohol related ESLD patients. Our study does not account for this
increase in liver transplantation.
Despite these limitations, the study has many advantages. To date, this is the largest study that
measures the utilization of palliative care and its impact on the care of patients with alcohol associated
liver disease. We utilized the largest and most inclusive readmission database in the United States.
These data are collected from all hospitals in 22 states, so these data are reasonably generalizable, and
we hope they will increase the validity of our study. We provided the first national estimate of 30-d
readmission risk specifically for alcohol-associated ESLD which are known to have poorer access to
healthcare in general and liver transplantation in particular. Also, we were able to grade patients using
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ACLF scoring to better ascertain the referral rate for palliative care depending on the clinical condition
of these patients.
The increase in adoption of PC for alcohol related ESLD suggests an increasing recognition of the role
PC plays in mitigating symptom burden and improving quality of life in these patients. Early palliative
care referrals[26], and easier access to high quality palliative care should be an integral part of managing
patients with alcohol related ESLD, and special attention needs to be paid to ensure inclusion of ethnic
minorities and patients of low socioeconomic status.

CONCLUSION
Inpatient palliative care is sparingly used for patients with decompensated alcohol related liver disease,
however it has increased over the past decade. Palliative care referral is associated with decreased
hospitalization cost and length of stay in ACLF positive alcohol-associated ESLD patients, as well as
decreased rehospitalization rates in all alcohol-associated ESLD patients.

ARTICLE HIGHLIGHTS
Research background
Use of palliative care (PC) consultation has been steadily increasing, especially in the field of cirrhosis.

Research motivation
Alcohol-associated end stage liver disease (ESLD) patients are at a disadvantage for being referred to
palliative care as they are younger and are more likely to belong to lower socioeconomic strata. The use
of palliative care is especially important for this subgroup as the only definite treatment is liver
transplant which is often not an option for these patients.

Research objectives
To assess the trend of PC use in patients hospitalized with alcohol associated ESLD as the primary
diagnosis, study the baseline characteristics of these patients, evaluate the factors associated with
increased PC use, study the impact of PC use on hospitalization outcomes and 30-d readmission rates.

Research methods
We used the national inpatient sample from 2007 to 2014, and the national readmission database from
2010 to 2014. We identified the patients admitted with alcoholic cirrhosis and at least one cirrhosis
decompensation event. We identified patients with PC consultation as a secondary diagnosis. Baseline
characteristics between the groups were compared with linear regression, and multivariate regression
analysis model was used to assess the impact that PC use has on the hospitalization outcomes.

Research results
PC use has increased over 8 times during the study period and was used in 6.6% of alcohol-associated
ESLD hospitalizations in 2014. PC use was more common in patients with ascites, hepatic encephalopathy and hepatocelluluar carcinoma. Other factors associated with increased PC use were females,
whites, uninsured patients, teaching hospitals and patients with a higher North American Consortium
for the Study of End-Stage Liver Disease's definition of acute-on-chronic liver failure score. The length
of stay and total hospitalization costs were lower in patients with acute-on-chronic liver failure score ≥ 2
and receiving PC, but not significantly different in the overall cohort. PC use was associated with
significantly lower 30-d readmission rates, with odds ratios of 0.35.

Research conclusions
PC use has been increasing over the years, however is still underutilized especially in select population
and in rural areas. We show that PC use is associated with decreased length of stay in patients with
more complications, and also leads to decreased 30-d readmission rates.

Research perspectives
This study calls for further research to assess the point during the disease course in which patients with
alcohol-associated ESLD would benefit from PC use. Further research should also be conducted to
assess for the reasons for decreased PC use in select disadvantaged population.
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